Valuation: Convatec Group Plc

Market Cap 6.13B 5.3B 4.95B 4.54B 8.54B 583B 8.68B 58.09B 22.8B 292B 23.02B 22.51B 967B P/E 2026 *
24.6x
P/E 2027 * 17.2x
Enterprise Value 7.48B 6.47B 6.04B 5.54B 10.42B 711B 10.58B 70.85B 27.81B 357B 28.07B 27.46B 1,179B EV / Sales 2026 *
2.92x
EV / Sales 2027 * 2.66x
Free-Float
95.19%
Yield 2026 *
2.53%
Yield 2027 * 2.87%
Manager TitleAgeSince
Chief Executive Officer 62 2025-08-03
Director of Finance/CFO 51 2025-08-03
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 71 2017-08-13
Chairman 78 2019-09-29
Director/Board Member 62 2020-03-01
Change 5-day change 1-year change 3-year change Capi.($)
-4.29%-.--% - - 6.13B
-0.14%+2.00%-19.71%+2.11% 187B
+1.44%+2.07%-6.16%+5.98% 112B
-1.40%+2.93%+12.39%+72.88% 61.15B
+0.65%+3.91%+32.37%+55.21% 54.39B
-0.12%+6.79%-8.60%-37.08% 48.17B
+2.08%+1.56%+7.47%-23.09% 31.98B
+2.09%-10.31% - - 30.91B
+1.57%+3.85%+46.93%-11.45% 24.92B
+2.45%+3.97%-2.22%+5.43% 23.15B
Average +0.43%+1.45%+7.81%+8.75% 63.64B
Weighted average by Cap. +0.48%+2.02%-1.67%+10.77%

Financials

2026 *2027 *
Net sales 2.56B 2.21B 2.06B 1.89B 3.56B 243B 3.62B 24.23B 9.51B 122B 9.6B 9.39B 403B 2.73B 2.36B 2.21B 2.02B 3.81B 260B 3.87B 25.89B 10.16B 130B 10.26B 10.03B 431B
Net income 248M 215M 201M 184M 346M 23.63B 351M 2.35B 923M 11.84B 932M 912M 39.15B 360M 311M 291M 267M 502M 34.27B 510M 3.41B 1.34B 17.17B 1.35B 1.32B 56.78B
Net Debt 1.35B 1.16B 1.09B 997M 1.88B 128B 1.91B 12.76B 5.01B 64.2B 5.05B 4.94B 212B 1.15B 992M 927M 850M 1.6B 109B 1.62B 10.87B 4.27B 54.73B 4.31B 4.21B 181B
Logo Convatec Group Plc
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA